Khurshid Iqbal, Ph.D.

Dr. Iqbal has over 25 + years of domestic and international experience in pharmaceutical product development. He has worked within the leading multinational pharmaceutical organizations, R.W. Johnson Pharmaceutical Research Institute, Hoffmann-La Roche and E.R. Squibb & Sons and last as Sr. Vice President and CSO at KBI Biopharma, Inc. Dr. Iqbal earned his Ph.D. in Pharmaceutics from The University of Sciences, Philadelphia and has remained active in the field of biopharmaceutical formulation development, drug delivery and stabilization of proteins and peptides. Dr. Iqbal has published consistently in this field and has extensive experience in formulations, drug delivery and product development of a variety of dosage forms, including sterile products, topicals, emulsions and suspensions. He was responsible for filing several INDs, NDAs and PLAs during his career with big pharma. He was elected as the section chair of the Biotech section of The American Association of Pharmaceutical Scientists, (AAPS) in 1992 and has remained active with the growth of this section at AAPS. He is a member of the Society of the Sigma Xi, AAPS, PDA and Controlled Release


Waheed Sheikh, Ph.D.

Dr. Waheed Sheikh,  co-founder and one of the principal consultants at STM Pharma Consulting, offers 30+ Years of extensive Industry Experience in both large and small Pharma companies. This includes ICI Pharmaceuticals, AstraZeneca, Roussel Laboratories and SL Pharma Labs, Inc. (a well reputed CRO/CDO, currently called Element/Exova after its sale in 2018) . He co-founded and successfully managed the company for ~ 20 years. During this period, Dr. Sheikh successfully managed, planned, executed and completed  numerous R&D drug development / CMC product development projects of a variety of dosage forms, notably Parenterals, Topicals, Ophthalmics, Intra-nasals and Antimicorbials for several domestic and international companies leading to regulatory approvals and commercialization. He offers special expertise in all aspects of Pharmaceutical Microbiology Technologies & Development and in the design of sterile facilities for both pharmaceutical industry and for compounding pharmacies. .He is completely familiar with FDA regulations/guidelines re Quality by Design, GMP-Compliance and CMC regulatory requirements for both generic and new drug products (all phases).

Dr. Sheikh has acquired high level of subject matter knowledge and expertise  in successful CMC development of a wide array of drug products, notably Parenterals, Topicals (both innovative and generics) & Microbiology, design of sterile facilities and offers valuable expertise in strategic, operational, and regulatory planning, FDA liaison, problem solving, leading to regulatory approvals and successful commercialization. He is a member of AAPS, PDA, and Delaware Bioscience Organization.